H
H. Miles Prince
Researcher at University of Melbourne
Publications - 345
Citations - 16762
H. Miles Prince is an academic researcher from University of Melbourne. The author has contributed to research in topics: Multiple myeloma & Internal medicine. The author has an hindex of 60, co-authored 313 publications receiving 14669 citations. Previous affiliations of H. Miles Prince include Monash University & Peter MacCallum Cancer Centre.
Papers
More filters
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Meletios A. Dimopoulos,Andrew Spencer,M. Attal,H. Miles Prince,Jean Luc Harousseau,Anna Dmoszynska,Jesús F. San Miguel,Andrzej Hellmann,Thierry Facon,Robin Foà,Alessandro Corso,Zvenyslava Masliak,Marta Olesnyckyj,Zhinuan Yu,John Patin,Jerome B. Zeldis,Robert Knight +16 more
TL;DR: Lenalidomide plus dexamethasone is more effective than high-dose dexamETHasone alone in relapsed or refractory multiple myeloma.
Journal ArticleDOI
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard Piekarz,Robin Frye,Maria L. Turner,John Wright,Steven L. Allen,Mark Kirschbaum,Jasmine Zain,H. Miles Prince,John P. Leonard,Larisa J. Geskin,Craig B. Reeder,David Joske,William D. Figg,Erin R. Gardner,Seth M. Steinberg,Elaine S. Jaffe,Maryalice Stetler-Stevenson,Stephen Lade,A. Tito Fojo,Susan E. Bates +19 more
TL;DR: The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
Journal ArticleDOI
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier,Barbara Pro,H. Miles Prince,Francine M. Foss,Lubomir Sokol,Matthew Greenwood,Dolores Caballero,Peter Borchmann,Franck Morschhauser,Martin Wilhelm,Lauren Pinter-Brown,Swaminathan Padmanabhan,Andrei R. Shustov,Jean Nichols,Susan Carroll,John Balser,Barbara Balser,Steven M. Horwitz +17 more
TL;DR: Single-agent romidepsin induced complete and durable responses with manageable toxicity in patients with relapsed or refractory peripheral T-cell lymphoma across all major PTCL subtypes, regardless of the number or type of prior therapies.
Journal ArticleDOI
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Elise A. Olsen,Sean Whittaker,Youn H. Kim,Madeleine Duvic,H. Miles Prince,Stuart R. Lessin,Gary S. Wood,Rein Willemze,Marie-France Demierre,Nicola Pimpinelli,Maria Grazia Bernengo,Pablo L. Ortiz-Romero,Martine Bagot,Teresa Estrach,Joan Guitart,Robert Knobler,José Antonio Sanches,Keiji Iwatsuki,Makoto Sugaya,Reinhard Dummer,Mark R. Pittelkow,Richard T. Hoppe,Sareeta Parker,Larisa J. Geskin,Lauren Pinter-Brown,Michael Girardi,Guenter Burg,Annamari Ranki,Maartan Vermeer,Steven M. Horwitz,Peter Heald,Steve Rosen,Lorenzo Cerroni,B. Dréno,Eric C. Vonderheid +34 more
TL;DR: In this article, consensus recommendations for the general conduct of clinical trials of patients with mycosis fungoides (MF) and Sezary syndrome (SS), as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, were presented.
Journal ArticleDOI
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard Piekarz,Robin Frye,H. Miles Prince,Mark Kirschbaum,Jasmine Zain,Steven L. Allen,Elaine S. Jaffe,Alexander Ling,Maria L. Turner,Cody J. Peer,William D. Figg,Seth M. Steinberg,Sonali M. Smith,David Joske,Ian D. Lewis,Laura F. Hutchins,Michael Craig,A. Tito Fojo,John J. Wright,Susan E. Bates +19 more
TL;DR: The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL and supported the approval of romidepsypsin for CTCL.